These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 37528157)

  • 1. HDAC1 and HDAC6 are essential for driving growth in IDH1 mutant glioma.
    Garrett MC; Albano R; Carnwath T; Elahi L; Behrmann CA; Pemberton M; Woo D; O'Brien E; VanCauwenbergh B; Perentesis J; Shah S; Hagan M; Kendler A; Zhao C; Paranjpe A; Roskin K; Kornblum H; Plas DR; Lu QR
    Sci Rep; 2023 Aug; 13(1):12433. PubMed ID: 37528157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IDH1 mutant glioma is preferentially sensitive to the HDAC inhibitor panobinostat.
    Sears TK; Horbinski CM; Woolard KD
    J Neurooncol; 2021 Sep; 154(2):159-170. PubMed ID: 34424450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutant Isocitrate Dehydrogenase 1 Expression Enhances Response of Gliomas to the Histone Deacetylase Inhibitor Belinostat.
    Chang CM; Ramesh KK; Huang V; Gurbani S; Kleinberg LR; Weinberg BD; Shim H; Shu HG
    Tomography; 2023 May; 9(3):942-954. PubMed ID: 37218937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.
    Lin L; Cai J; Tan Z; Meng X; Li R; Li Y; Jiang C
    Cancer Res Treat; 2021 Apr; 53(2):367-377. PubMed ID: 33070553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation.
    Li S; Chou AP; Chen W; Chen R; Deng Y; Phillips HS; Selfridge J; Zurayk M; Lou JJ; Everson RG; Wu KC; Faull KF; Cloughesy T; Liau LM; Lai A
    Neuro Oncol; 2013 Jan; 15(1):57-68. PubMed ID: 23115158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EZH2 Inhibition Sensitizes IDH1R132H-Mutant Gliomas to Histone Deacetylase Inhibitor.
    Sprinzen L; Garcia F; Mela A; Lei L; Upadhyayula P; Mahajan A; Humala N; Manier L; Caprioli R; Quiñones-Hinojosa A; Casaccia P; Canoll P
    Cells; 2024 Jan; 13(3):. PubMed ID: 38334611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological modulation of HDAC1 and HDAC6 in vivo in a zebrafish model: Therapeutic implications for Parkinson's disease.
    Pinho BR; Reis SD; Guedes-Dias P; Leitão-Rocha A; Quintas C; Valentão P; Andrade PB; Santos MM; Oliveira JM
    Pharmacol Res; 2016 Jan; 103():328-39. PubMed ID: 26657418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vulnerability of IDH1-Mutant Cancers to Histone Deacetylase Inhibition via Orthogonal Suppression of DNA Repair.
    Dow J; Krysztofiak A; Liu Y; Colon-Rios DA; Rogers FA; Glazer PM
    Mol Cancer Res; 2021 Dec; 19(12):2057-2067. PubMed ID: 34535560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic therapy of cancer with histone deacetylase inhibitors.
    Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
    J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.
    Turcan S; Fabius AW; Borodovsky A; Pedraza A; Brennan C; Huse J; Viale A; Riggins GJ; Chan TA
    Oncotarget; 2013 Oct; 4(10):1729-36. PubMed ID: 24077826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Demethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide.
    Yamashita AS; da Costa Rosa M; Borodovsky A; Festuccia WT; Chan T; Riggins GJ
    Neuro Oncol; 2019 Feb; 21(2):189-200. PubMed ID: 30184215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone deacetylase inhibitors exert anti-tumor effects on human adherent and stem-like glioma cells.
    Was H; Krol SK; Rotili D; Mai A; Wojtas B; Kaminska B; Maleszewska M
    Clin Epigenetics; 2019 Jan; 11(1):11. PubMed ID: 30654849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas.
    Chou AP; Chowdhury R; Li S; Chen W; Kim AJ; Piccioni DE; Selfridge JM; Mody RR; Chang S; Lalezari S; Lin J; Sanchez DE; Wilson RW; Garrett MC; Harry B; Mottahedeh J; Nghiemphu PL; Kornblum HI; Mischel PS; Prins RM; Yong WH; Cloughesy T; Nelson SF; Liau LM; Lai A
    J Natl Cancer Inst; 2012 Oct; 104(19):1458-69. PubMed ID: 22945948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered cancer cell metabolism in gliomas with mutant IDH1 or IDH2.
    Borodovsky A; Seltzer MJ; Riggins GJ
    Curr Opin Oncol; 2012 Jan; 24(1):83-9. PubMed ID: 22080945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-tumour activity of Panobinostat in oesophageal adenocarcinoma and squamous cell carcinoma cell lines.
    Lopes N; Salta S; Flores BT; Miranda-Gonçalves V; Correia MP; Gigliano D; Guimarães R; Henrique R; Jerónimo C
    Clin Epigenetics; 2024 Aug; 16(1):102. PubMed ID: 39097736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential expression of the TWEAK receptor Fn14 in IDH1 wild-type and mutant gliomas.
    Hersh DS; Peng S; Dancy JG; Galisteo R; Eschbacher JM; Castellani RJ; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
    J Neurooncol; 2018 Jun; 138(2):241-250. PubMed ID: 29453678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis.
    Korfei M; Stelmaszek D; MacKenzie B; Skwarna S; Chillappagari S; Bach AC; Ruppert C; Saito S; Mahavadi P; Klepetko W; Fink L; Seeger W; Lasky JA; Pullamsetti SS; Krämer OH; Guenther A
    PLoS One; 2018; 13(11):e0207915. PubMed ID: 30481203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence.
    Turcan S; Makarov V; Taranda J; Wang Y; Fabius AWM; Wu W; Zheng Y; El-Amine N; Haddock S; Nanjangud G; LeKaye HC; Brennan C; Cross J; Huse JT; Kelleher NL; Osten P; Thompson CB; Chan TA
    Nat Genet; 2018 Jan; 50(1):62-72. PubMed ID: 29180699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas.
    Wang HY; Tang K; Liang TY; Zhang WZ; Li JY; Wang W; Hu HM; Li MY; Wang HQ; He XZ; Zhu ZY; Liu YW; Zhang SZ
    J Exp Clin Cancer Res; 2016 May; 35():86. PubMed ID: 27245697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation.
    Duncan CG; Barwick BG; Jin G; Rago C; Kapoor-Vazirani P; Powell DR; Chi JT; Bigner DD; Vertino PM; Yan H
    Genome Res; 2012 Dec; 22(12):2339-55. PubMed ID: 22899282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.